363 related articles for article (PubMed ID: 31974016)
1. Porcine circovirus type 2a or 2b based experimental vaccines provide protection against PCV2d/porcine parvovirus 2 co-challenge.
Opriessnig T; Karuppannan AK; Halbur PG; Calvert JG; Nitzel GP; Matzinger SR; Meng XJ
Vaccine; 2020 Feb; 38(8):1975-1981. PubMed ID: 31974016
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a porcine circovirus type 2a (PCV2a) vaccine efficacy against experimental PCV2a, PCV2b, and PCV2d challenge.
Park KH; Oh T; Yang S; Cho H; Kang I; Chae C
Vet Microbiol; 2019 Apr; 231():87-92. PubMed ID: 30955830
[TBL] [Abstract][Full Text] [Related]
3. A PCV2 vaccine based on genotype 2b is more effective than a 2a-based vaccine to protect against PCV2b or combined PCV2a/2b viremia in pigs with concurrent PCV2, PRRSV and PPV infection.
Opriessnig T; O'Neill K; Gerber PF; de Castro AM; Gimenéz-Lirola LG; Beach NM; Zhou L; Meng XJ; Wang C; Halbur PG
Vaccine; 2013 Jan; 31(3):487-94. PubMed ID: 23174198
[TBL] [Abstract][Full Text] [Related]
4. A Porcine circovirus type 2b (PCV2b)-based experimental vaccine is effective in the PCV2b-Mycoplasma hyopneumoniae coinfection pig model.
Opriessnig T; Castro AMMG; Karuppanan AK; Gauger PC; Halbur PG; Matzinger SR; Meng XJ
Vaccine; 2019 Oct; 37(44):6688-6695. PubMed ID: 31537445
[TBL] [Abstract][Full Text] [Related]
5. A commercial porcine circovirus (PCV) type 2a-based vaccine reduces PCV2d viremia and shedding and prevents PCV2d transmission to naïve pigs under experimental conditions.
Opriessnig T; Xiao CT; Halbur PG; Gerber PF; Matzinger SR; Meng XJ
Vaccine; 2017 Jan; 35(2):248-254. PubMed ID: 27919634
[TBL] [Abstract][Full Text] [Related]
6. Commercial PCV2a-based vaccines are effective in protecting naturally PCV2b-infected finisher pigs against experimental challenge with a 2012 mutant PCV2.
Opriessnig T; Gerber PF; Xiao CT; Halbur PG; Matzinger SR; Meng XJ
Vaccine; 2014 Jul; 32(34):4342-8. PubMed ID: 24929119
[TBL] [Abstract][Full Text] [Related]
7. Cellular and humoral immunity following vaccination with two different PCV2 vaccines (containing PCV2a or PCV2a/PCV2b) and challenge with virulent PCV2d.
Venegas-Vargas C; Taylor LP; Foss DL; Godbee TK; Philip R; Bandrick M
Vaccine; 2021 Sep; 39(39):5615-5625. PubMed ID: 34420789
[TBL] [Abstract][Full Text] [Related]
8. Inactivated chimeric porcine circovirus (PCV) 1-2 vaccines based on genotypes 2b and 2d exhibit similar immunological effectiveness in protecting pigs against challenge with PCV2b strain 0233.
Li J; Yu T; Zhang F; Wang X; Zhou J; Gao X; Gao S; Liu X
Arch Virol; 2017 Jan; 162(1):235-246. PubMed ID: 27722993
[TBL] [Abstract][Full Text] [Related]
9. Comparison of three commercial one-dose porcine circovirus type 2 (PCV2) vaccines in a herd with concurrent circulation of PCV2b and mutant PCV2b.
Jeong J; Park C; Choi K; Chae C
Vet Microbiol; 2015 May; 177(1-2):43-52. PubMed ID: 25790733
[TBL] [Abstract][Full Text] [Related]
10. A chimeric virus created by DNA shuffling of the capsid genes of different subtypes of porcine circovirus type 2 (PCV2) in the backbone of the non-pathogenic PCV1 induces protective immunity against the predominant PCV2b and the emerging PCV2d in pigs.
Matzinger SR; Opriessnig T; Xiao CT; Catanzaro N; Beach NM; Slade DE; Nitzel GP; Meng XJ
Virology; 2016 Nov; 498():82-93. PubMed ID: 27564544
[TBL] [Abstract][Full Text] [Related]
11. An experimental live chimeric porcine circovirus 1-2a vaccine decreases porcine circovirus 2b viremia when administered intramuscularly or orally in a porcine circovirus 2b and porcine reproductive and respiratory syndrome virus dual-challenge model.
Opriessnig T; Gomes-Neto JC; Hemann M; Shen HG; Beach NM; Huang Y; Halbur PG; Meng XJ
Microbiol Immunol; 2011 Dec; 55(12):863-73. PubMed ID: 21951266
[TBL] [Abstract][Full Text] [Related]
12. A live-attenuated chimeric porcine circovirus type 2 (PCV2) vaccine is transmitted to contact pigs but is not upregulated by concurrent infection with porcine parvovirus (PPV) and porcine reproductive and respiratory syndrome virus (PRRSV) and is efficacious in a PCV2b-PRRSV-PPV challenge model.
Opriessnig T; Shen HG; Pal N; Ramamoorthy S; Huang YW; Lager KM; Beach NM; Halbur PG; Meng XJ
Clin Vaccine Immunol; 2011 Aug; 18(8):1261-8. PubMed ID: 21653745
[TBL] [Abstract][Full Text] [Related]
13. A commercial PCV2a-based vaccine is effective in protection from experimental challenge of PCV2 mutant with two amino acids elongation in capsid protein.
Guo LJ; Fu YJ; Huang LP; Wang YP; Wei YW; Wu HL; Liu CM
Vaccine; 2015 Jul; 33(31):3752-7. PubMed ID: 26051516
[TBL] [Abstract][Full Text] [Related]
14. A candidate DNA vaccine encoding a fusion protein of porcine complement C3d-P28 and ORF2 of porcine circovirus type 2 induces cross-protective immunity against PCV2b and PCV2d in pigs.
Hou Z; Wang H; Feng Y; Li Q; Li J
Virol J; 2019 May; 16(1):57. PubMed ID: 31046793
[TBL] [Abstract][Full Text] [Related]
15. A commercial vaccine based on PCV2a and an experimental vaccine based on a variant mPCV2b are both effective in protecting pigs against challenge with a 2013 U.S. variant mPCV2b strain.
Opriessnig T; Gerber PF; Xiao CT; Mogler M; Halbur PG
Vaccine; 2014 Jan; 32(2):230-7. PubMed ID: 24269319
[TBL] [Abstract][Full Text] [Related]
16. Porcine circovirus type 2 (PCV2) genotyping in Austrian pigs in the years 2002 to 2017.
Weissenbacher-Lang C; Kristen T; Mendel V; Brunthaler R; Schwarz L; Weissenböck H
BMC Vet Res; 2020 Jun; 16(1):198. PubMed ID: 32539835
[TBL] [Abstract][Full Text] [Related]
17. Capsid proteins from PCV2a genotype confer greater protection against a PCV2b strain than those from PCV2b genotype in pigs: evidence for PCV2b strains becoming more predominant than PCV2a strains from 2000 to 2010s.
Huang L; Wang Y; Wei Y; Chen D; Liu D; Du W; Xia D; Wu H; Feng L; Liu C
Appl Microbiol Biotechnol; 2016 Jul; 100(13):5933-43. PubMed ID: 27020283
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of cross-immunity among major porcine circovirus type 2 genotypes by infection with PCV2b and PCV2d circulating strains.
Yu C; Cao M; Wei Y; Liu J; Zhang H; Liu C; Feng L; Huang L
Vet Microbiol; 2023 Aug; 283():109796. PubMed ID: 37285792
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of cell-mediated immune responses against porcine circovirus type 2 (PCV2) Cap and Rep proteins after vaccination with a commercial PCV2 sub-unit vaccine.
Fort M; Sibila M; Nofrarías M; Pérez-Martín E; Olvera A; Mateu E; Segalés J
Vet Immunol Immunopathol; 2012 Nov; 150(1-2):128-32. PubMed ID: 23010221
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and phylogenetic analysis of the current porcine circovirus 2 genotypes after implementation of widespread vaccination programmes in the USA.
Shen HG; Halbur PG; Opriessnig T
J Gen Virol; 2012 Jun; 93(Pt 6):1345-1355. PubMed ID: 22398315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
